Get started
Author

Hristina I. Pashova

Tooth wear: prevalence and associated factors in general practice patients
2010 · Joana Cunha‐Cruz, Hristina Pashova, et al. · Community Dentistry And Oral Epidemiology · 89
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 · Alexander B Olawaiye, Laurence Gladieff, et al. · The Lancet · 79
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
2023 · Nicoletta Colombo, Toon Van Gorp, et al. · Journal of Clinical Oncology · 52
PDF
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
2022 · Pamela N. Munster, Andrew E. Greenstein, et al. · Clinical Cancer Research · 44
Association between caries location and restorative material treatment provided
2011 · Erinne B. Lubisich, Thomas J. Hilton, et al. · Journal of Dentistry · 22
721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
2021 · N. Colombo, D.D. Nguyen, et al. · Annals of Oncology · 12
Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis
2015 · Pradeep Suri, Hristina Pashova, et al. · Spine · 8
Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.
2023 · Michael J. Morris, Mark David Linch, et al. · Journal of Clinical Oncology · 6
Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
2022 · Nicoletta Colombo, Toon Van Gorp, et al. · Journal of Clinical Oncology · 6
PDF
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
2025 · Alexander Olawaiye, Laurence Gladieff, et al. · Journal of Clinical Oncology · 5
PDF
Boosting for detection of gene–environment interactions
2012 · H. Pashova, M. LeBlanc, et al. · Statistics in Medicine · 5
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
2026 · Lucy Gilbert, Benoit You, et al. · Journal of Clinical Oncology · 3
PDF
LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
2025 · D. Lorusso, S. Quesada, et al. · Annals of Oncology · 3
PDF
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study
2024 · Erkut H Borazanci, Nathan Bahary, et al. · The Oncologist · 3
PDF
Comparing healthcare utilization patterns via global differences in the endorsement of current procedural terminology codes
2017 · Xu Shi, Hristina Pashova, et al. · The Annals of Applied Statistics · 3
PDF
Structured Detection of Interactions with the Directed Lasso
2016 · Hristina Pashova, Michael LeBlanc, et al. · Statistics in Biosciences · 3
ROSELLA (GOG3073, engotov72, APGOT-OV10): a phase 3 study of relacorilant + nab-paclitaxel in patients with platinum-resistant ovarian cancer
2026 · Domenica Lorusso, Stanislas Quesada, et al. · International Journal of Gynecological Cancer · 2
1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
2025 · D. Lorusso, B.J. Monk, et al. · Annals of Oncology · 2
PDF
Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)
2025 · Richard J. Auchus, Aleksandra Gilis-Januszewska, et al. · Metabolism · 1
ROSELLA – GOG-3073 – ENGOT-OV72/MITO: A phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer (1241)
2023 · Alexander Olawaiye, Toon Van Gorp, et al. · Gynecologic Oncology · 1
PDF
536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study
2022 · N. Colombo, T. Van Gorp, et al. · Annals of Oncology · 1
1397P Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
2022 · M. Linch, G. Liu, et al. · Annals of Oncology · 1
PDF
Final Overall Survival Results From the Phase 3 Rosella Trial: Relacorilant Plus Nab-paclitaxel Vs Nab-paclitaxel Monotherapy in Patients With Platinum-resistant Ovarian Cancer
2026 · Alexander Olawaiye, Stanislas Quesada, et al. · International Journal of Gynecological Cancer
SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.
2026 · Omid Hamid, Jose Maria Pacheco, et al. · Journal of Clinical Oncology
TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
2026 · Erkut H. Borazanci, Drew W. Rasco, et al. · Journal of Clinical Oncology
PDF
Works count: 40
Citation count: 351
H-index: 7
I10-index: 6
Year
Topic
Type